fenofibrate has been researched along with Acute Necrotizing Pancreatitis in 3 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
Excerpt | Relevance | Reference |
---|---|---|
"To report a case of acute necrotizing pancreatitis associated with simvastatin and fenofibrate use." | 3.71 | Pancreatitis associated with simvastatin plus fenofibrate. ( Garber, BG; McDonald, KB; Perreault, MM, 2002) |
"In a patient with diabetic ketoacidosis complicated by severe elevation of plasma triglyceride concentrations, treatment with low-level intravenous unfractionated heparin led to prompt reduction in plasma triglyceride concentration and may have prevented the development of hypertriglyceridemia-associated acute pancreatitis." | 1.35 | Heparin treatment for severe hypertriglyceridemia in diabetic ketoacidosis. ( Cole, RP, 2009) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (66.67) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cole, RP | 1 |
Whayne, TF | 1 |
McDonald, KB | 1 |
Garber, BG | 1 |
Perreault, MM | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
FEnofibRate as a Metabolic INtervention for Coronavirus Disease 2019[NCT04517396] | Phase 2 | 701 participants (Actual) | Interventional | 2020-08-18 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Death from any cause during the observation period (NCT04517396)
Timeframe: Up to 30 days
Intervention | Participants (Count of Participants) |
---|---|
Fenofibrate + Usual Care | 19 |
Placebo + Usual Care | 22 |
The exploratory global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) The number of days out of the hospital during the 30 day-period following randomization. (NCT04517396)
Timeframe: Up to 30 days
Intervention | score on a scale (Median) |
---|---|
Fenofibrate + Usual Care | 5.03 |
Placebo + Usual Care | 5.03 |
Number of days that participants were alive and out of the hospital during the 30 days following randomization (NCT04517396)
Timeframe: Up to 30 days
Intervention | days (Median) |
---|---|
Fenofibrate + Usual Care | 30 |
Placebo + Usual Care | 30 |
Number of days participants were alive, out of the intensive care unit, free of mechanical ventilation/extracorporeal membrane oxygenation, or maximal available respiratory support during the 30 days that followed randomization (NCT04517396)
Timeframe: Up to 30 days
Intervention | days (Mean) |
---|---|
Fenofibrate + Usual Care | 28.8 |
Placebo + Usual Care | 28.3 |
The primary endpoint of the trial is a global rank score that ranks patient outcomes according to 5 factors. The global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) For participants enrolled as outpatients who are subsequently hospitalized, the number of days out of the hospital during the 30 day-period following randomization; (5) For participants enrolled as outpatients who don't get hospitalized during the 30-day observation period, the modified Borg dyspnea scale (NCT04517396)
Timeframe: 30 days
Intervention | Ranked Severity Score (Median) |
---|---|
Fenofibrate + Usual Care | 5.32 |
Placebo + Usual Care | 5.33 |
The secondary global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) For participants enrolled as outpatients who are subsequently hospitalized, the number of days out of the hospital during the 30 day-period following randomization; (5) For participants enrolled as outpatients who don't get hospitalized during the 30-day observation period, a COVID-19 symptom scale rating fever, cough, dyspnea, muscle aches, sore throat, loss of smell or taste, headache, diarrhea, fatigue, nausea/vomiting, chest pain (each are rated from 0-10 then summed). (NCT04517396)
Timeframe: Up to 30 days
Intervention | score on a scale (Median) |
---|---|
Fenofibrate + Usual Care | 5.05 |
Placebo + Usual Care | 5.05 |
A seven-category ordinal scale consisting of the following categories: 1, not hospitalized with resumption of normal activities; 2, not hospitalized, but unable to resume normal activities; 3, hospitalized, not requiring supplemental oxygen; 4, hospitalized, requiring supplemental oxygen; 5, hospitalized, requiring nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both; 6, hospitalized, requiring extracorporeal membrane oxygenation (ECMO), invasive mechanical ventilation, or both; and 7, death. (NCT04517396)
Timeframe: At 15 days
Intervention | score on a scale (Median) |
---|---|
Fenofibrate + Usual Care | 1 |
Placebo + Usual Care | 1 |
3 other studies available for fenofibrate and Acute Necrotizing Pancreatitis
Article | Year |
---|---|
Heparin treatment for severe hypertriglyceridemia in diabetic ketoacidosis.
Topics: Atorvastatin; Cholesterol; Diabetic Ketoacidosis; Dose-Response Relationship, Drug; Drug Therapy, Co | 2009 |
Concerns about heparin therapy for hypertriglyceridemia.
Topics: Atorvastatin; Cholesterol; Chylomicrons; Diabetic Ketoacidosis; Dose-Response Relationship, Drug; Dr | 2010 |
Pancreatitis associated with simvastatin plus fenofibrate.
Topics: Aged; Drug Therapy, Combination; Fatal Outcome; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic | 2002 |